Jason Harris

Ponatinib (Iclusig) induced a complete remission in one pediatric/adolescent patient with Philadelphia chromosome-positive acute lymphoblastic leukemia, and demonstrated promising clinical activity in another.

Tocilizumab resolved cytokine release syndrome in patients with relapsed/refractory pediatric B-cell acute lymphoblastic leukemia without reducing the efficacy of tisagenlecleucel.

The US Preventive Services Task Force has concluded that there is a small mortality benefit associated with prostate-specific antigen-based prostate cancer screening for men aged 55 to 69 years, a departure from earlier guidance.

There is very little evidence of clinical validity or clinical utility to justify the widespread use of circulating tumor DNA assays in most patients with advanced cancer, according to a panel of experts from ASCO and the College of American Pathologists

In updated guidelines exploring the role of bone-modifying agents, ASCO has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma.

Both cognitive behavior therapy for insomnia (CBT-I) and acupuncture produced clinically meaningful improvements in insomnia severity scores for cancer survivors, but data from the randomized CHOICE clinical trial showed that CBT-I was more effective overall for reducing the severity of insomnia.

President Donald Trump announced a sweeping “blueprint” to lower prescription drug costs, promising to expand access to generic drugs and biosimilars and remove incentives that keep drug prices high.

Radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 nearly doubled median PSA progression-free survival in men with progressive metastatic castrate-resistant prostate cancer compared with previous results with radium-223.

Discontinuation of tyrosine kinase inhibitor treatment may be a possibility for children with chronic myeloid leukemia and, because they could be on-treatment for decades, treatment-free remission is even more important for pediatric patients than for adults.

Eltrombopag (Promacta) boosted the platelet count in a 13-year-old boy with HIV-associated thrombocytopenia, according to case study results presented at the 2018 American Society of Pediatric Hematology/Oncology Conference.

The Children's Oncology Group is currently involved in 5 studies exploring targeted therapies in non-Hodgkin lymphoma (NHL) that could eventually change the face of pediatric NHL treatment.

A first-time study of chimeric antigen receptor T-cell therapy in youths with Down syndrome-associated relapsed/refractory (r/r) acute lymphoblastic leukemia produced high remission rates and toxicity results that were similar to those observed in patients with r/r ALL.

Tazemetostat demonstrated promising antitumor activity in pediatric patients with INI1-negative solid tumors.

Eliminating T cells carrying alpha and beta chains of the T-cell receptor reduced the risk for graft-versus-host-disease while producing "excellent" engraftment kinetics for young patients with acute leukemia who underwent hematopoietic stem cell transplant.

2B8T2M, a fusion of the IL-15 superantagonist ALT-803, and 4 single-chains of rituximab (Rituxan) significantly boosted the cytotoxicity of expanded peripheral blood natural killer cells against Burkitt lymphoma cells in in vitro testing.

Results from a recent study may show why some patients with chronic lymphocytic leukemia are resistant to tisagenlecleucel, while potentially offering a pathway to enhance patient response.

CAR T-cell therapy can induce next generation sequencing negativity in patients with relapsed/refractory acute lymphoblastic leukemia, suggesting a "synergistic" relationship with hematopoietic cell transplant.

Adolescent and young adult patients with cancer placed a high importance on prognostic information, and obtaining that knowledge was associated with improved well-being.

Carboxyamidotriazole orotate in combination with temozolomide, with or without radiotherapy, produced positive safety and efficacy results in a phase Ib study of patients with glioblastoma or anaplastic gliomas.

Everolimus demonstrated strong potential as an effective tool for overcoming endocrine resistance in postmenopausal women with ER-positive, HER2-negative metastatic breast cancer resistant to AI therapy.

A novel risk stratification and treatment approach led to enhanced clinical outcomes overall, as well as the successful omission of radiotherapy for some patients with stage IV favorable histology Wilms tumor and pulmonary metastases.

An oncologist-led BRCA mutation testing pathway in the ENGAGE study has led researchers to conclude that pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors.

The combination of nivolumab and ipilimumab more than tripled the 1-year progression-free survival rate versus chemotherapy for treatment-naïve patients with non–small cell lung cancer with high tumor mutation burden.

The FDA has announced plans to ease the development of genetic and genomic-based tests and introduced guidelines designed to accelerate the submission process for investigational cancer drugs and biological products.

Investigators found that autologous stem-cell transplantation improved overall survival and reduced treatment-related mortality in patients with immunoglobulin light chain amyloidosis.

Crizotinib induced a nearly 72% overall response rate and a median progression-free survival of almost 16 months in a single-arm phase II trial of 127 patients with ROS1-positive advanced non–small cell lung cancer (NSCLC).

The combination of nivolumab and ipilimumab induced an intracranial response of 46% in melanoma patients with asymptomatic, untreated brain metastases.

An analysis of clinical characteristics, gene expression, and 21-gene Breast Recurrence Score results identified distinctive biologic features of breast cancer in men.

The combination of venetoclax and ibrutinib induced a 16-week complete response rate of 42% per CT imaging in patients with previously untreated or relapsed/refractory mantle cell lymphoma.

Ramucirumab extended overall survival versus placebo as a second-line treatment for patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein, according to findings from the phase III REACH-2 trial.